GH Research (NASDAQ:GHRS) Stock Price Expected to Rise, Guggenheim Analyst Says

GH Research (NASDAQ:GHRS – Get Free Report) had its price objective hoisted by equities researchers at Guggenheim from $40.00 to $46.00 in a note issued to investors on Wednesday, Marketbeat reports. The brokerage presently has a “buy” rating on the stock. Guggenheim‘s target price suggests a potential upside of 147.84% from the stock’s previous close.

Several other brokerages have also commented on GHRS. New Street Research set a $65.00 price objective on GH Research in a report on Monday, August 10th. Cantor Fitzgerald lifted their target price on shares of GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. HC Wainwright cut their price target on shares of GH Research from $65.00 to $55.00 and set a “buy” rating for the company in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a report on Thursday, October 15th. Finally, Needham & Company LLC raised their price objective on shares of GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $44.00.

Check Out Our Latest Stock Report on GHRS

GH Research Stock Performance

Shares of GHRS stock opened at $18.56 on Wednesday. GH Research has a 52-week low of $12.04 and a 52-week high of $31.44. The company has a market capitalization of $1.27 billion, a PE ratio of -19.54 and a beta of 1.31. The business’s fifty day moving average is $21.56 and its 200 day moving average is $21.69.

GH Research (NASDAQ:GHRS – Get Free Report) last posted its earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.13. On average, sell-side analysts forecast that GH Research will post -1.08 EPS for the current fiscal year.

Institutional Trading of GH Research

A number of hedge funds have recently bought and sold shares of GHRS. Royal Bank of Canada grew its position in GH Research by 43.1% during the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock valued at $36,000 after acquiring an additional 780 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of GH Research in the 3rd quarter worth approximately $82,000. Bellevue Group AG purchased a new stake in shares of GH Research in the 3rd quarter valued at $109,000. Farther Finance Advisors LLC grew its holdings in shares of GH Research by 9,720.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 9,820 shares of the company’s stock valued at $231,000 after purchasing an additional 9,720 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of GH Research during the 1st quarter valued at $290,000. Institutional investors own 56.90% of the company’s stock.

Top GH Research Stories

Investors following GHRS have been watching these stories:

  • Positive Sentiment: HC Wainwright revised several forecasts to smaller expected losses, including FY2026 EPS from ($1.14) to ($1.00) and FY2027 from ($1.62) to ($1.59). It kept its Buy rating and $55 price target. The revisions are modestly encouraging, though the firm still forecasts losses. GH Research analyst estimates
  • Positive Sentiment: Guggenheim recently raised its price target to $46 from $40 and maintained a Buy rating, signaling a more favorable view of GH Research’s prospects. Guggenheim stock recommendations
  • Negative Sentiment: A separate report said GH Research shares fell 6.9% following an analyst downgrade. The provided report does not identify the analyst or explain the downgrade, but it adds near-term pressure and contrasts with the Buy ratings from HC Wainwright and Guggenheim. GH Research shares down on analyst downgrade

About GH Research

(Get Free Report)

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.

Further Reading

Analyst Recommendations for GH Research (NASDAQ:GHRS)

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.